FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Citigroup Expands Coinbase Partnership for Stablecoin Payments 
BitMine Ethereum Holdings Top 6 Million ETH After $46 Million Purchase 
Trump Bans CNN, MS NOW and Politico From White House 
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
RedotPay Completes Audits as Stablecoin Firm Advances U.S. IPO Plans 
China Tightens Fentanyl Rules Ahead of Trump-Xi Summit 
Anthropic Targets $2 Trillion Valuation in Planned IPO 
China Reviews Broadcom Switch Use in State Data Centres 
Strategy Buys 1,665 Bitcoin as BTC Holdings Reach 847,666 
Morgan Stanley Raises TD Synnex Price Target to $359 on Strong AI Demand 
DOJ Will Investigate AI-Related Crimes, Attorney General Blanche Says 
Nvidia China Chip Sales Report Sends Chinese Semiconductor Stocks Lower 
Trump Scales Back Endangered Species Act Protections 
Add as a preferred source on Google
HUTCHMED said Tuesday that AstraZeneca has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for a combination therapy aimed at treating patients with advanced lung cancer.
The regulatory application covers the ORPATHYS-TAGRISSO combination, bringing the treatment closer to potential availability in the U.S. market if it receives FDA clearance. The submission represents an important regulatory step for HUTCHMED and AstraZeneca as the companies continue developing new targeted treatment options for lung cancer patients.
ORPATHYS is being jointly developed by HUTCHMED and AstraZeneca, while AstraZeneca is responsible for the drug's commercialization. The collaboration combines HUTCHMED's oncology drug development capabilities with AstraZeneca's global commercial reach and established presence in lung cancer treatment.
The proposed therapy pairs ORPATHYS with TAGRISSO, AstraZeneca's established lung cancer medicine. Combination therapies have become an important area of oncology research as pharmaceutical companies seek treatment approaches capable of addressing complex disease pathways and improving outcomes for patients with advanced cancers.
The FDA application could expand the companies' presence in the competitive U.S. lung cancer treatment market. Regulatory approval would also represent a significant milestone for the ORPATHYS development program and strengthen the broader oncology partnership between HUTCHMED and AstraZeneca.
The companies have been working together to advance ORPATHYS as part of their efforts to develop precision medicines for cancer patients. AstraZeneca's responsibility for commercialization means the pharmaceutical group would oversee bringing the combination treatment to market following any required regulatory approvals.
Investors and the healthcare industry will now be watching the FDA review process for the ORPATHYS-TAGRISSO combination. A potential approval would add another treatment option for eligible patients with advanced lung cancer while marking further progress for HUTCHMED and AstraZeneca's joint oncology development strategy.
